YAVNE, Israel--(BUSINESS WIRE)--MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that MediWound’s management team will be presenting the Company’s corporate overview at the following investor conferences in November.
- The Credit Suisse 2014 Healthcare Conference taking place from November 10-13, 2014 at The Arizona Biltmore in Phoenix, Arizona. Gal Cohen, President and Chief Executive Officer of MediWound, will deliver the corporate presentation on Tuesday, November 11th at 1:30 p.m. local time.
- The Jefferies 2014 Global Healthcare Conference taking place from November 19-20th at the Waldorf Hilton Hotel – Aldwych in London. Mr. Cohen will deliver the corporate presentation on Wednesday, November 19th at 3:00 p.m. local time.
Live webcasts of both presentations can be accessed by visiting the investors section of the company’s website at www.mediwound.com. A replay of the webcasts will be archived on the MediWound website for 90 days following each respective presentation.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has been launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.